Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $231

Benzinga Newsdesk www.benzinga.com Positive 65.7%

Neg 0% Neu 0% Pos 65.7%

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $222 to $231.